Danielle Carroll

Danielle Carroll is an Executive Director in Oncology Translational Medicine with over 15 years of experience in oncology research across academia and the biotech/pharmaceutical sectors. They currently lead a team of over ten scientists focused on a novel oncolytic viral therapy for cancer treatment. Previously, Danielle has held roles at Harvard Medical School, AstraZeneca, and MedImmune, among others, where they contributed to key projects in drug discovery and clinical strategy. They hold a PhD in Cell and Molecular Biology from the University of Cambridge and have extensive experience in translational medicine strategies involving monoclonal antibodies and biologic drugs.